Korean J Urol Oncol.  2020 Aug;18(2):. 10.22465/kjuo.2020.18.2.99.

New Androgen Receptor Axis-Targeted Agents inthe Treatment of Nonmetastatic Castration-ResistantProstate Cancer: From Bench to Clinical Trials

Affiliations
  • 1Department of Urology, Dankook University College of Medicine, Cheonan, Korea

Abstract

Bone metastasis is a common sign of disease progression in nonmetastatic castration-resistant prostate cancer(nmCRPC). It has been known to be associated with significant morbidity and mortality. Delaying or preventingdevelopment of distant metastasis is the ideal goal of treatment. There had been no standard treatment optionsavailable for patients with nmCRPC before 2018. Recent approval of new androgen receptor axis-targeted agentsin the management of nmCRPC has led to rapid evolution and is worthy of detailed investigation.

Keyword

Castration-resistant prostate neoplasms; Neoplasm metastasis; Androgen receptor antagonists
Full Text Links
  • KJUO
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr